Cormorant Asset Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Cormorant Asset Management’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100K	Buy	+5,498	New	+$126K	0.01%	50

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cormorant Asset Management's IRLA Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026: 5,498 shares worth $100K. The stake represents 0.01% of the portfolio and ranks #50 among its holdings.

26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Cormorant Asset Management held 5,498 shares of IRulya Therapeutics Inc. Common Stock worth $100K as of Q2 2026.
IRulya Therapeutics Inc. Common Stock was a new Cormorant Asset Management position in Q2 2026.
IRulya Therapeutics Inc. Common Stock made up 0.01% of Cormorant Asset Management's portfolio in Q2 2026, its #50 holding.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.